IL276287B1 - Use of (1S,3S)-3-amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, sensorineural hearing loss, Meniere's disease, Tourette's syndrome, attention deficit hyperactivity disorder, and addiction - Google Patents

Use of (1S,3S)-3-amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, sensorineural hearing loss, Meniere's disease, Tourette's syndrome, attention deficit hyperactivity disorder, and addiction

Info

Publication number
IL276287B1
IL276287B1 IL276287A IL27628720A IL276287B1 IL 276287 B1 IL276287 B1 IL 276287B1 IL 276287 A IL276287 A IL 276287A IL 27628720 A IL27628720 A IL 27628720A IL 276287 B1 IL276287 B1 IL 276287B1
Authority
IL
Israel
Prior art keywords
amino
carboxylic acid
difluoromethylenyl
difluoromethylidene
meniere
Prior art date
Application number
IL276287A
Other languages
English (en)
Hebrew (he)
Other versions
IL276287A (en
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of IL276287A publication Critical patent/IL276287A/en
Publication of IL276287B1 publication Critical patent/IL276287B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL276287A 2018-02-08 2019-02-08 Use of (1S,3S)-3-amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, sensorineural hearing loss, Meniere's disease, Tourette's syndrome, attention deficit hyperactivity disorder, and addiction IL276287B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862628020P 2018-02-08 2018-02-08
US201862628541P 2018-02-09 2018-02-09
PCT/US2019/017201 WO2019157273A1 (en) 2018-02-08 2019-02-08 Use of (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, meniere's disease, tourette's syndrome, attention deficit hyperactivity disorder and addiction

Publications (2)

Publication Number Publication Date
IL276287A IL276287A (en) 2020-09-30
IL276287B1 true IL276287B1 (en) 2026-07-01

Family

ID=67475310

Family Applications (1)

Application Number Title Priority Date Filing Date
IL276287A IL276287B1 (en) 2018-02-08 2019-02-08 Use of (1S,3S)-3-amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, sensorineural hearing loss, Meniere's disease, Tourette's syndrome, attention deficit hyperactivity disorder, and addiction

Country Status (10)

Country Link
US (1) US10653652B2 (cg-RX-API-DMAC7.html)
EP (1) EP3735237A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021512920A (cg-RX-API-DMAC7.html)
KR (3) KR20240154700A (cg-RX-API-DMAC7.html)
CN (1) CN112261938A (cg-RX-API-DMAC7.html)
AU (1) AU2019216742B2 (cg-RX-API-DMAC7.html)
CA (1) CA3090258A1 (cg-RX-API-DMAC7.html)
IL (1) IL276287B1 (cg-RX-API-DMAC7.html)
MX (1) MX2020008359A (cg-RX-API-DMAC7.html)
WO (1) WO2019157273A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX389001B (es) 2015-10-23 2025-03-20 Navitor Pharm Inc Moduladores de interacción de sestrina-gator2 y sus usos.
ES3040534T3 (en) 2017-04-26 2025-11-03 Navitor Pharm Inc Modulator of sestrin-gator2 interaction for use in the treatment of treatment-resistant depression
US11771671B2 (en) 2018-02-08 2023-10-03 Ovid Therapeutics Inc. Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, attention deficit hyperactivity disorder and addiction
AU2019243586A1 (en) * 2018-03-29 2020-10-15 Ovid Therapeutics Inc. Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of eye disorders
WO2020086816A1 (en) 2018-10-24 2020-04-30 Navitor Pharmaceuticals, Inc. Polymorphic compounds and uses thereof
AU2020376950B2 (en) 2019-11-01 2026-06-11 Supernus Pharmaceuticals, Inc. Methods of treatment using an mTORC1 modulator
US12678586B1 (en) 2023-06-12 2026-07-14 John Brundage Noise injury relief system

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6656172B1 (en) * 2002-09-27 2003-12-02 Medtronic, Inc. Method for treating severe tinnitus
US20140336256A1 (en) * 2012-01-27 2014-11-13 Catalyst Pharmaceutical Partners Method of treating tourette's disorder with gaba-aminotransferase inactivators
WO2017062942A2 (en) * 2015-10-09 2017-04-13 Northwestern University (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid, and related compounds as gaba aminotransferase inactivators for the treatment of epilepsy, addiction and hepatocellular carcinoma

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794413B1 (en) * 2002-07-19 2004-09-21 Northwestern University Compounds and related methods for inhibition of γ-aminobutyric acid aminotransferase
JP2009517393A (ja) * 2005-11-28 2009-04-30 オレキシジェン・セラピューティクス・インコーポレーテッド 不安症の治療方法
CA2790820A1 (en) 2010-02-25 2011-09-01 Northwestern University Use (1s,3s)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid as a gaba aminotransferse inhibitor
US20130230586A1 (en) * 2010-10-02 2013-09-05 Link Research & Grants Corporation Treatment of Tinnitus and Related Auditory Dysfunctions
WO2013006857A1 (en) 2011-07-07 2013-01-10 The Children's Hospital Of Philadelphia Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatment of autism
ES2862673T3 (es) * 2011-12-12 2021-10-07 Zilentin AG Tratamiento del tinnitus mediante la modulación del cotransportador de cloruro NKCC1 en el sistema auditivo
KR20240110989A (ko) 2017-02-08 2024-07-16 오비드 테라퓨틱스 인크. 프라더-윌리 증후군 및 발작 장애들을 치료하는 방법들

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6656172B1 (en) * 2002-09-27 2003-12-02 Medtronic, Inc. Method for treating severe tinnitus
US20140336256A1 (en) * 2012-01-27 2014-11-13 Catalyst Pharmaceutical Partners Method of treating tourette's disorder with gaba-aminotransferase inactivators
WO2017062942A2 (en) * 2015-10-09 2017-04-13 Northwestern University (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid, and related compounds as gaba aminotransferase inactivators for the treatment of epilepsy, addiction and hepatocellular carcinoma

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LE, HOANG V., ET AL., DESIGN AND MECHANISM OF TETRAHYDROTHIOPHENE-BASED GAMMA-AMINOBUTYRIC ACID AMINOTRANSFERASE INACTIVATORS, 17 March 2015 (2015-03-17) *

Also Published As

Publication number Publication date
MX2020008359A (es) 2020-11-24
KR20240154700A (ko) 2024-10-25
JP2021512920A (ja) 2021-05-20
KR20250167147A (ko) 2025-11-28
WO2019157273A1 (en) 2019-08-15
CN112261938A (zh) 2021-01-22
CA3090258A1 (en) 2019-08-15
US20190240174A1 (en) 2019-08-08
KR20210007948A (ko) 2021-01-20
EP3735237A4 (en) 2021-03-17
EP3735237A1 (en) 2020-11-11
AU2019216742A1 (en) 2020-08-13
IL276287A (en) 2020-09-30
AU2019216742B2 (en) 2024-05-09
US10653652B2 (en) 2020-05-19